| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09.24 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 | 562 | GlobeNewswire (Europe) | Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations... ► Artikel lesen | |
| 14.09.24 | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) ... | 385 | GlobeNewswire (Europe) | Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority... ► Artikel lesen | |
| 14.09.24 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its ... | 567 | GlobeNewswire (Europe) | Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant... ► Artikel lesen | |
| 14.09.24 | Transgene S.A.: Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments | 636 | GlobeNewswire (Europe) | Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma... ► Artikel lesen | |
| 14.09.24 | Sutro Biopharma, Inc.: Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 | 600 | GlobeNewswire (Europe) | - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian... ► Artikel lesen | |
| 14.09.24 | Immunocore Holdings plc: Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer | 661 | GlobeNewswire (Europe) | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy... ► Artikel lesen | |
| 14.09.24 | IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer | 610 | GlobeNewswire (Europe) | -- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals... ► Artikel lesen | |
| 14.09.24 | Greystone Logistics Inc.: Greystone Logistics Reports Strong Year-End Earnings | 168 | GlobeNewswire (Europe) | TULSA, Okla., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Greystone Logistics, ("Greystone Logistics" or the "Company") (OTCQB:GLGI) the leading manufacturer of recycled plastic pallets providing sustainable... ► Artikel lesen | |
| 14.09.24 | VERSES AI Inc. Announces 2024 AGSM Results | 843 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (the "Company" or "VERSES") (CBOE Canada: VERS) (OTCQX: VRSSF) is pleased to announce the results of the Annual General... ► Artikel lesen | |
| 14.09.24 | NuCana plc: NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 | 533 | GlobeNewswire (Europe) | Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety ProfileBARCELONA, Spain... ► Artikel lesen | |
| 14.09.24 | Avacta Group: Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors | 522 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act... ► Artikel lesen | |
| 14.09.24 | iTeos Therapeutics Inc. Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients | 743 | GlobeNewswire (Europe) | - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 601 |
| EVOTEC | 334 |
| NOVO NORDISK | 323 |
| TESLA | 291 |
| RHEINMETALL | 246 |
| BYD | 233 |
| RENK GROUP | 170 |
| DEUTZ | 162 |
| TUI | 135 |
| APPLE | 132 |
| BASF | 132 |
| VOLKSWAGEN | 130 |
| STEYR MOTORS | 128 |
| NETFLIX | 127 |
| BAYER | 126 |
| PLUG POWER | 122 |
| AMAZON | 117 |
| UNITEDHEALTH | 114 |
| ALMONTY | 113 |
| XIAOMI | 108 |
| COMMERZBANK | 107 |
| E.ON | 105 |
| NEL | 105 |
| RWE | 105 |
| SIEMENS ENERGY | 100 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
